China SXT Pharmaceuticals, Inc.
SXTC Nasdaq
SEC CIK 1723980
Follow China SXT Pharmaceuticals
Weekly email: filings, results, news
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY26 | $1.1M | −$6.2M |
| FY25 | $1.7M | −$3.3M |
| FY24 | $1.9M | −$3.1M |
| FY23 | $2M | −$5.9M |
| FY22 | $2.6M | −$5.7M |
| FY21 | $4.8M | −$2.7M |
| FY20 | $5.2M | −$10.3M |
| FY19 | $7M | $1.5M |
| FY18 | $7M | $1.2M |
| FY17 | $4.9M | $1.2M |
| FY16 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY26 | 21.9% | −625.9% | −545.2% |
| FY25 | 21.1% | −154% | −189.8% |
| FY24 | 28.7% | −130.4% | −160.7% |
| FY23 | 21.6% | −284.4% | −301% |
| FY22 | 48.1% | −199.4% | −220.4% |
| FY21 | 59.4% | −46% | −57.5% |
| FY20 | 52.4% | −26% | −199.3% |
| FY19 | 65.8% | 25.2% | 22% |
| FY18 | 48.5% | 23.3% | 16.9% |
| FY17 | 47.4% | 32.8% | 24.3% |
| FY16 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY26 | - |
| FY25 | −$2.3M |
| FY24 | −$1.9M |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | $803.4K |
| FY19 | −$296.6K |
| FY18 | $1.5M |
| FY17 | $113.9K |
| FY16 | - |
- China SXT Pharmaceuticals
- Healthcare median
Show the numbers
| Year | China SXT Pharmaceuticals | Healthcare median |
|---|---|---|
| FY26 | −545.2% | −19.9% |
| FY25 | −189.8% | −40.6% |
| FY24 | −160.7% | −60.7% |
| FY23 | −301% | −97.1% |
| FY22 | −220.4% | −128.5% |
| FY21 | −57.5% | −129.2% |
| FY20 | −199.3% | −136.5% |
| FY19 | 22% | −133.7% |
| FY18 | 16.9% | −173.4% |
| FY17 | 24.3% | −176.7% |
| FY16 | - | −164.8% |
News
No stories filed under China SXT Pharmaceuticals yet - coverage appears here as the news feed clusters it.